Hodgkin lymphoma treatment for older persons in the modern era.

Autor:	Evens AM; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., McKenna M; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Ryu Tiger YK; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Upshaw JN; Division of Cardiology, Tufts Medical Center, Boston, MA.
Jazyk:	angličtina
Zdroj:	Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2023 Dec 08; Vol. 2023 (1), pp. 483-499.
DOI:	10.1182/hematology.2023000449
Abstrakt:	There has been a renewed effort globally in the study of older Hodgkin lymphoma (HL) patients, generating a multitude of new data. For prognostication, advancing age, comorbidities, altered functional status, Hispanic ethnicity, and lack of dose intensity (especially without anthracycline) portend inferior survival. Geriatric assessments (GA), including activities of daily living (ADL) and comorbidities, should be objectively measured in all patients. In addition, proactive multidisciplinary medical management is recommended (eg, geriatrics, cardiology, primary care), and pre-phase therapy should be considered for most patients. Treatment for fit older HL patients should be given with curative intent, including anthracyclines, and bleomycin should be minimized (or avoided). Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy for untreated patients is tolerable and effective, and frontline checkpoint inhibitor/AVD platforms are rapidly emerging. Therapy for patients who are unfit or frail, whether due to comorbidities and/or ADL loss, is less clear and should be individualized with consideration of attenuated anthracycline-based therapy versus lower-intensity regimens with inclusion of brentuximab vedotin +/- checkpoint inhibitors. For all patients, there should be clinical vigilance with close monitoring for treatment-related toxicities, including neurotoxicity, cardiopulmonary, and infectious complications. Finally, active surveillance for "postacute" complications 1 to 10 years post therapy, especially cardiac disease, is needed for cured patients. Altogether, therapy for older HL patients should include anthracycline-based therapy in most cases, and novel targeted agents should continue to be integrated into treatment paradigms, with more research needed on how best to utilize GAs for treatment decisions. (Copyright © 2023 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu